Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
J Neurol Neurosurg Psychiatry ; 78(4): 419-22, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17158557

RESUMEN

BACKGROUND: Antibodies with reactivity to peripheral nerve myelin have previously been found in the serum, and bound to peripheral nerves of patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). AIM: To investigate the presence of antibodies reactive to specific peptide sequences within the myelin proteins P0 and P2 in patients with GBS, in patients with CIDP, in healthy controls and in patients with other neuropathies (ON). METHODS: Blood was obtained from 48 patients with GBS, 36 with CIDP, 48 with ON and 38 controls. ELISA was used to detect antibody responses to peptides of the human peripheral myelin proteins P0 and P2. Blood samples were collected from patients with GBS in early, peak and recovery stages of GBS to analyse antibody levels throughout the course of the disease. RESULTS: Significantly increased total IgG levels were found in patients with GBS compared with other groups. A higher percentage of patients with GBS at the peak of disease had antibody reactivity to P2(14-25) compared with patients with CIDP and control groups. In patients with GBS and CIDP, the percentages of patients with antibody reactivity to P2(61-70), and peptides derived from P0, were comparable to the control groups. Although some individual patients with GBS had high titres of reactivity to the peptide antigens tested, most patients with GBS and CIDP had levels of antibody similar to controls. CONCLUSION: Our data suggest that increased IgG levels and increased antibody reactivity to P2(14-25) in patients with GBS at the peak of disease may play a contributory role in the disease process in some patients with demyelinating forms of GBS.


Asunto(s)
Síndrome de Guillain-Barré/inmunología , Proteína P0 de la Mielina/inmunología , Proteína P2 de Mielina/inmunología , Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante/inmunología , Estudios de Casos y Controles , Progresión de la Enfermedad , Ensayo de Inmunoadsorción Enzimática , Humanos , Inmunoglobulina G/análisis , Enfermedades del Sistema Nervioso/inmunología
2.
Gut ; 53(10): 1509-15, 2004 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-15361505

RESUMEN

INTRODUCTION: The delay of several days between an erythropoietic stimulus and the subsequent increase in intestinal iron absorption is commonly believed to represent the time required for body signals to programme the immature crypt enterocytes and for these cells to migrate to the villus. Recent data however suggest that signals from the body to alter absorption are mediated by circulating hepcidin and that this peptide exerts its effect on mature villus enterocytes. METHODS: We have examined the delay in the absorptive response following stimulated erythropoiesis using phenylhydrazine induced haemolysis and correlated this with expression of hepcidin in the liver and iron transporters in the duodenum. RESULTS: There was a delay of four days following haemolysis before a significant increase in iron absorption was observed. Hepatic hepcidin expression did not decrease until day 3, reaching almost undetectable levels by days 4 and 5. This coincided with the increase in duodenal expression of divalent metal transporter 1, duodenal cytochrome b, and Ireg1. CONCLUSION: These results suggest that the delayed increase in iron absorption following stimulated erythropoiesis is attributable to a lag in the hepcidin response rather than crypt programming, and are consistent with a direct effect of the hepcidin pathway on mature villus enterocytes.


Asunto(s)
Péptidos Catiónicos Antimicrobianos/metabolismo , Eritropoyesis/fisiología , Absorción Intestinal/fisiología , Hierro/metabolismo , Análisis de Varianza , Animales , Regulación de la Expresión Génica/fisiología , Hemólisis/efectos de los fármacos , Hemólisis/fisiología , Hepcidinas , Hígado/metabolismo , Masculino , Fenilhidrazinas/farmacología , Ratas , Ratas Sprague-Dawley , Factores de Tiempo , Transferrina/metabolismo
3.
J Biochem ; 122(1): 101-8, 1997 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9276677

RESUMEN

We produced an anti-paraquat single chain antibody (scFv) to investigate its potential use in immunotherapy for paraquat poisoning. However, this scFv was expressed in an insoluble form and only displayed moderate binding affinity. An earlier examination of the pH dependence of antigen binding by the parent paraquat-specific mAb (7D7-3) suggested that the electrostatic effects of a tyrosine residue were important. The aims of the current study were to obtain expression of a soluble scFv (D10) and to increase its binding affinity. The former was achieved by expression in a phagemid vector. Site-directed mutagenesis of tyrosine residues in CDR H3 did not result in improved affinity for paraquat, suggesting that the original pH dependence required re-examination. Nuclear magnetic resonance studies of 7D7-3 Fab revealed that the original observation of the pH-dependent paraquat binding with a mid-point of approximately pH 8.9 was due to tightly bound Tris. It appears that as Tris is titrated to a neutral species the energetically unfavourable juxtaposition of its positive charge with that of paraquat is reduced. These findings have broad implications in the interpretation of the pH or salt dependence of any antibody-antigen interaction which should be made cautiously and with regard to the possible interference of buffer components introduced during the preparation of the antibody.


Asunto(s)
Anticuerpos/metabolismo , Fragmentos de Inmunoglobulinas/genética , Fragmentos de Inmunoglobulinas/metabolismo , Paraquat/inmunología , Trometamina/química , Animales , Anticuerpos/genética , Secuencia de Bases , Clonación Molecular , Electroforesis/métodos , Concentración de Iones de Hidrógeno , Espectroscopía de Resonancia Magnética , Ratones , Mutagénesis Sitio-Dirigida , Paraquat/química , Paraquat/metabolismo , Trometamina/metabolismo , Tirosina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...